Loss of angiotensin-converting enzyme 2 enhances TGF-Β/Smad-mediated renal fibrosis and NF-κB-driven renal inflammation in a mouse model of obstructive nephropathy

Laboratory Investigation

Volumn 92, Issue 5, 2012, Pages 650-661

  Liu, Zhen ^a   Huang, Xiao Ru ^a   Chen, Hai Yong ^a   Penninger, Josef M ^b   Lan, Hui Yao ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Smads; Ace2; NF kB; Renal fibrosis and inflammation; Smad7; Smurf2; TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; COLLAGEN TYPE 1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; SMURF2 PROTEIN; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; MALE; MOLECULAR PATHOLOGY; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UNILATERAL URETERAL OBSTRUCTIVE NEPHROPATHY; UPREGULATION; URETER OBSTRUCTION; WILD TYPE;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; KIDNEY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEPHRITIS; NF-KAPPA B; PEPTIDYL-DIPEPTIDASE A; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN-PROTEIN LIGASES; URETERAL OBSTRUCTION;

EID: 84860296188     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.2     Document Type: Article

References (42)

1. Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens 2010;20:1-6.
2. Koka V, Huang XR, Chung AC, et al. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008;172:1174-1183. (Pubitemid 351671532)
3. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 2006;98:463-471.
4. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2010;20:62-68.
5. Soler MJ, Wysocki J, Ye M, et al. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocininduced diabetic mice. Kidney Int 2007;72:614-623. (Pubitemid 47312795)
6. Ye M, Wysocki J, William J, et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006;17:3067-3075. (Pubitemid 44707767)
7. Oudit GY, Herzenberg AM, Kassiri Z, et al. Loss of angiotensinconverting enzyme-2 leads to the late development of angiotensin IIdependent glomerulosclerosis. Am J Pathol 2006;168:1808-1820. (Pubitemid 43825302)
8. Wong DW, Oudit GY, Reich H, et al. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007;171:438-451. (Pubitemid 47344677)
9. Zhong J, Guo D, Chen CB, et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensinconverting enzyme 2. Hypertension 2011;57:314-322.
10. Oudit GY, Liu GC, Zhong J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010; 59:529-538.
11. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822-828. (Pubitemid 34670323)
12. Chung AC, Huang XR, Zhou L, et al. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 2009;24:1443-1454.
13. Lan HY, Mu W, Nikolic-Paterson DJ, et al. A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 1995;43:97-102.
14. Chen HY, Huang XR, Wang W, et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 2011;60:590-601.
15. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, et al. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 2005;111:2509-2517. (Pubitemid 40696140)
16. Wang W, Huang XR, Canlas E, et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 2006;98:1032-1039.
17. Yang F, Chung AC, Huang XR, et al. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and-independent Smad pathways: the role of Smad3. Hypertension 2009;54:877-884.
18. Tikellis C, Cooper ME, Bialkowski K, et al. Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int 2006; 70:34-41. (Pubitemid 44000118)
19. Dilauro M, Zimpelmann J, Robertson SJ, et al. Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. Am J Physiol Renal Physiol 2010;298:F1523-F1532.
20. Kamilic J, Hamming I, Kreutz R, et al. Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27. Hypertens Res 2009;33:123-128.
21. Wysocki J, Ye M, Soler MJ, et al. ACE and ACE2 activity in diabetic mice. Diabetes 2006;55:2132-2139. (Pubitemid 44509989)
22. Ye M, Wysocki J, Naaz P, et al. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004;43:1120-1125. (Pubitemid 38579924)
23. Lely AT, Hamming I, van Goor H, et al. Renal ACE2 expression in human kidney disease. J Pathol 2004;204:587-593. (Pubitemid 39585958)
24. Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008;51:613-623. (Pubitemid 351400834)
25. Reich HN, Oudit GY, Penninger JM, et al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008;74:1610-1616.
26. Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003;41:392-397. (Pubitemid 36314606)
27. Shiota A, Yamamoto K, Ohishi M, et al. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin- induced diabetic mice. Hypertens Res 2010;33: 298-307.
28. Mizuiri S, Hemmi H, Arita M, et al. Increased ACE and decreased ACE2 expression in kidneys from patients with IgA nephropathy. Nephron Clin Pract 2010;117:c57-c66.
29. Zhuo JL, Li XC. New insights and perspectives on intrarenal reninangiotensin system: focus on intracrine/intracellular angiotensin II. Peptides 2011;32:1551-1565.
30. Navar LG, Kobori H, Prieto MC, et al. Intratubular renin-angiotensin system in hypertension. Hypertension 2011;57:355-362.
31. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006;17:2985-2991. (Pubitemid 44707758)
32. Zhuo JL, Li XC. Novel roles of intracrine angiotensin II and signalling mechanisms in kidney cells. J Renin Angiotensin Aldosterone Syst 2007;8:23-33. (Pubitemid 46779545)
33. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656-665.
34. Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci 2008;13:4984-4992.
35. Kavsak P, Rasmussen RK, Causing CG, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000;6:1365-1375. (Pubitemid 32045929)
36. Yang F, Huang XR, Chung AC, et al. Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition. J Pathol 2010;221:390-401.
37. Fukasawa H, Yamamoto T, Togawa A, et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 2004;101:8687-8692. (Pubitemid 38745832)
38. Ng YY, Hou CC, Wang W, et al. Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int Suppl 2005; S83-S91.
39. Wang W, Huang XR, Li AG, et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 2005;16:1371-1383. (Pubitemid 41716521)
40. Lan HY, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003;14:1535-1548. (Pubitemid 36687055)
41. Hou CC, Wang W, Huang XR, et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factorbeta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005;166:761-771. (Pubitemid 40315633)
42. Ka SM, Huang XR, Lan HY, et al. Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 2007;18:1777-1788.